| Emerging trends in the stabilization of amorphous drugs R Laitinen, K Löbmann, CJ Strachan, H Grohganz, T Rades International journal of pharmaceutics 453 (1), 65-79, 2013 | 509 | 2013 |
| Recent advances in co-amorphous drug formulations SJ Dengale, H Grohganz, T Rades, K Löbmann Advanced drug delivery reviews 100, 116-125, 2016 | 462 | 2016 |
| Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen K Löbmann, R Laitinen, H Grohganz, KC Gordon, C Strachan, T Rades Molecular pharmaceutics 8 (5), 1919-1928, 2011 | 390 | 2011 |
| Amino acids as co-amorphous stabilizers for poorly water soluble drugs–Part 1: Preparation, stability and dissolution enhancement K Löbmann, H Grohganz, R Laitinen, C Strachan, T Rades European journal of pharmaceutics and biopharmaceutics 85 (3), 873-881, 2013 | 329 | 2013 |
| Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions K Löbmann, C Strachan, H Grohganz, T Rades, O Korhonen, R Laitinen European Journal of Pharmaceutics and Biopharmaceutics 81 (1), 159-169, 2012 | 247 | 2012 |
| Design space approach in the optimization of the spray-drying process P Lebrun, F Krier, J Mantanus, H Grohganz, M Yang, E Rozet, ... European Journal of Pharmaceutics and Biopharmaceutics 80 (1), 226-234, 2012 | 205 | 2012 |
| Amino acids as co-amorphous stabilizers for poorly water-soluble drugs–Part 2: Molecular interactions K Löbmann, R Laitinen, C Strachan, T Rades, H Grohganz European Journal of Pharmaceutics and Biopharmaceutics 85 (3), 882-888, 2013 | 203 | 2013 |
| Recent trends in stabilising peptides and proteins in pharmaceutical formulation–considerations in the choice of excipients L Jorgensen, S Hostrup, EH Moeller, H Grohganz Expert opinion on drug delivery 6 (11), 1219-1230, 2009 | 185 | 2009 |
| Refining stability and dissolution rate of amorphous drug formulations H Grohganz, PA Priemel, K Löbmann, LH Nielsen, R Laitinen, A Mullertz, ... Expert opinion on drug delivery 11 (6), 977-989, 2014 | 151 | 2014 |
| Improving co-amorphous drug formulations by the addition of the highly water soluble amino acid, proline KT Jensen, K Löbmann, T Rades, H Grohganz Pharmaceutics 6 (3), 416-435, 2014 | 144 | 2014 |
| Preparation and characterization of spray-dried co-amorphous drug–amino acid salts KT Jensen, LI Blaabjerg, E Lenz, A Bohr, H Grohganz, P Kleinebudde, ... Journal of Pharmacy and Pharmacology 68 (5), 615-624, 2016 | 131 | 2016 |
| A theoretical and spectroscopic study of co-amorphous naproxen and indomethacin K Löbmann, R Laitinen, H Grohganz, C Strachan, T Rades, KC Gordon International journal of pharmaceutics 453 (1), 80-87, 2013 | 131 | 2013 |
| Glass-transition temperature of the β-relaxation as the major predictive parameter for recrystallization of neat amorphous drugs EO Kissi, H Grohganz, K Löbmann, MT Ruggiero, JA Zeitler, T Rades The Journal of Physical Chemistry B 122 (10), 2803-2808, 2018 | 130 | 2018 |
| Supersaturating drug delivery systems: the potential of co-amorphous drug formulations R Laitinen, K Löbmann, H Grohganz, P Priemel, CJ Strachan, T Rades International Journal of Pharmaceutics 532 (1), 1-12, 2017 | 122 | 2017 |
| Amino acids as co-amorphous excipients for simvastatin and glibenclamide: physical properties and stability R Laitinen, K Lobmann, H Grohganz, C Strachan, T Rades Molecular pharmaceutics 11 (7), 2381-2389, 2014 | 122 | 2014 |
| Co-amorphous drug formulations in numbers: Recent advances in co-amorphous drug formulations with focus on co-formability, molar ratio, preparation methods, physical stability … J Liu, H Grohganz, K Löbmann, T Rades, NJ Hempel Pharmaceutics 13 (3), 389, 2021 | 115 | 2021 |
| Solid-state properties and dissolution behaviour of tablets containing co-amorphous indomethacin–arginine E Lenz, KT Jensen, LI Blaabjerg, K Knop, H Grohganz, K Löbmann, ... European Journal of Pharmaceutics and Biopharmaceutics 96, 44-52, 2015 | 105 | 2015 |
| Development of a screening method for co-amorphous formulations of drugs and amino acids G Kasten, H Grohganz, T Rades, K Löbmann European Journal of Pharmaceutical Sciences 95, 28-35, 2016 | 101 | 2016 |
| Co-former selection for co-amorphous drug-amino acid formulations G Kasten, K Löbmann, H Grohganz, T Rades International journal of pharmaceutics 557, 366-373, 2019 | 100 | 2019 |
| Formation mechanism of coamorphous drug–amino acid mixtures KT Jensen, FH Larsen, C Cornett, K Löbmann, H Grohganz, T Rades Molecular pharmaceutics 12 (7), 2484-2492, 2015 | 98 | 2015 |
